Table 21Quality of life outcomes for pharmacological versus pharmacological interventions

Intervention AIntervention BBotherDaily ActivitiesDistressGeneral HealthMental HealthPainSexual HealthSleep/Energy
Anticholinergic vs. anticholinergicOxybutyninTolterodine1 (90):
 1 NS		1 (90):
 1 NS
OxybutyninTrospium chloride1 (90):
 1 NS		1 (90):
 1 NS
Oxybutynin 2.6 mgOxybutynin 3.9 mg1 (254):
 1 favor† B
SolifenacinDarifenacin1 (76):
 1 NS		1 (76):
 1 disc
Anticholinergic vs. onabotulinum toxin ASolifenacinOnabotulinum toxin A1 (247):
 1 NS
Anticholinergic vs. anticholinergic and hormonal therapyFesoterodineFesoterodine, vaginal estrogen1 (18):
 1 NS		1 (18):
 1 NS
Anticholinergic vs. antiepilepticTolterodinePregabalin1 (178):
 1 NS
Tolterodine + pregabalinPregabalin1 (178):
 1 NS

Empty cells indicate that the intervention was not evaluated for the outcome designated in the given column

Abbreviations: disc = discordant findings; NS = non-significant.

*

Results are given as number of studies (number of people), number of studies with significant difference and which intervention it favors, number of studies with discordant results (that is, within the same study, significant differences favoring one intervention were found on one scale or subscale, but nonsignificant differences were found on others, number of studies with nonsignificant differences.

†

Favor indicates a statistically significant (net) difference favoring the specified intervention.

From: Results

Cover of Nonsurgical Treatments for Urinary Incontinence in Women: A Systematic Review Update
Nonsurgical Treatments for Urinary Incontinence in Women: A Systematic Review Update [Internet].
Comparative Effectiveness Review, No. 212.
Balk E, Adam GP, Kimmel H, et al.
Copyright Notice

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.